Suppr超能文献

[测试无麻黄碱麻黄草提取物效用的临床研究]

[Clinical Research Testing the Usefulness of Ephedrine Alkaloids-free Ephedra Herb Extract].

作者信息

Odaguchi Hiroshi

机构信息

Oriental Medicine Research Center, Kitasato University.

出版信息

Yakugaku Zasshi. 2017;137(2):195-197. doi: 10.1248/yakushi.16-00233-6.

Abstract

We aimed to test the clinical usefulness of ephedrine alkaloids-free Ephedra Herb extract (EFE), which has been proven to be effective and safe in animal studies. First, we performed a safety trial with 7 healthy volunteers, and increased white blood cell counts were observed in 2. However, it was unknown whether this observation was a result of EFE administration. Then, we implemented a controlled, double-blind, randomized crossover trial as the second safety trial for EFE. The trial was conducted under strict conditions, and the participants were managed in the hospital and monitored using an increased number of endpoints. Twelve healthy volunteers were randomly allocated to group 1, who were administered EFE first, or group 2, who were administered Ephedra Herb first. In both groups, the drug was administered for 6 d. After a 4-week washout period with no drug administration, each group was administered the alternate drug for 6 d. In the third stage, a dose-response trial is planned to test the effectiveness and safety of EFE on chronic joint pain. Patients with chronic knee joint pain will be randomly allocated to three groups, and each group will be administered EFE prepared from different amounts of Ephedra Herb. Until this stage, the studies will be conducted as investigator-initiated clinical trials. In the fourth stage, industry-sponsored clinical trials will be planned. This multicenter trial will involve 300 patients with joint pain, neuralgia, and/or muscle pain.

摘要

我们旨在测试不含麻黄生物碱的麻黄草提取物(EFE)的临床实用性,该提取物在动物研究中已被证明是有效且安全的。首先,我们对7名健康志愿者进行了安全性试验,其中2人观察到白细胞计数增加。然而,尚不清楚这一观察结果是否是EFE给药的结果。然后,我们实施了一项对照、双盲、随机交叉试验,作为EFE的第二项安全性试验。该试验在严格条件下进行,参与者在医院接受管理,并使用更多的终点指标进行监测。12名健康志愿者被随机分配到第1组,先给予EFE,或第2组,先给予麻黄草。在两组中,药物均给药6天。在为期4周的无药物洗脱期后,每组给予替代药物6天。在第三阶段,计划进行剂量反应试验,以测试EFE对慢性关节疼痛的有效性和安全性。慢性膝关节疼痛患者将被随机分配到三组,每组将给予由不同量麻黄草制备的EFE。在这个阶段之前,研究将作为研究者发起的临床试验进行。在第四阶段,将计划进行行业赞助的临床试验。这项多中心试验将涉及300名有关节疼痛、神经痛和/或肌肉疼痛的患者。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验